Febuxostat (Uloric) and its problem with cardiovascular mortality

Last Updated on

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons. Febuxostat (Uloric) was approved by the American Food and Drug Administration (FDA) in 2009 for the chronic management of hyperuricemia in patients with gout. One condition of the approval of Febuxostat (Uloric) in 2009 was that a postmarketing safety study be conducted by Takeda Pharmaceuticals America, Inc. The postmarketing safety trial required by the FDA was called Cardiovascular Safety of Febuxostat (Uloric) and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES).
In March 2018 it was announced that this CARES trial found that Febuxostat (Uloric) was inexplicably linked to more cardiac deaths than was Allopurinol, the mainstay drug for patients with gout and cardiovascular disease. As a consequence, on January 10, 2019, the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee panelists discussed the potential biological mechanisms behind cardiovascular (CV) events associated with the use of Febuxostat (Uloric) and its seemingly heightened risk for unwanted cardiovascular events.

The panelists came to the conclusion that for the general population with gout, the benefits of Febuxostat (Uloric) would not outweigh the risks (particularly cardiovascular events) when compared to Allopurinol, one of the standard treatments in patients with gout. In contrast, they proposed that the benefits of urate-lowering Febuxostat (Uloric) outweigh its risks for selected gout patients, though only for unrestricted access only as a second-line therapy, mostly for individuals who have had a serious skin reaction to or otherwise “absolutely don’t tolerate” Allopurinol, the mainstay xanthine oxidase inhibitor for uric acid reduction.

In this context, it is noteworthy that Febuxostat (Uloric)’s label already warns of increased risk of gout flares with initiation of therapy, cardiovascular events, hepatic toxicity, and serious skin reactions. Panelists further recommended several regulatory actions such as an additional black box warning and a change in the indication to label Febuxostat (Uloric) as a second-line therapy after Allopurinol only. They kept it open, if even a recall of Febuxostat (Uloric) could be considered.

Further to the status at the time of this writing, the FDA has now added a “Boxed Warning” to the drug label of Febuxostat (Uloric) due to the obvious increased risk of death for patients under Febuxostat (Uloric) and introduce a new, strengthened patient Medication Guide. FDA  also limits the approved use of Uloric to certain patients who are not treated effectively or experience severe side effects with Allopurinol.  See here the according safety communication by the FDA as of February 02, 2019.

See here an video introductory to gout:

Print Friendly, PDF & Email

Tags: , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login

0 Comment threads
0 Thread replies
Most reacted comment
Hottest comment thread
0 Comment authors
Recent comment authors
Notify of

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Researchers identify new gene mutation in familial thyroid cancers November 20, 2019
    Researchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer. Dr. Darrin Bann, an otolaryngology resident at the College of Medicine and lead author of the study, said that this mutation is the first and only mutation associated with familial thyroid cancer to be […]
  • Researchers develop new database of druggable fusion targets November 20, 2019
    When sections from two separate genes merge due to various factors, such as translocation or splicing, the hybrid that is formed is called a gene fusion. In recent years, it has been discovered that these fusion events play a vital role in the development of cancers and other complex diseases. However, there are very few […]
  • Early results of CRISPR gene-editing treatment shows promise in first human trials November 20, 2019
    Officials from Vertex Pharmaceuticals and CRISPR Therapeutics have announced that preliminary results from testing CRISPR gene-editing treatment in human patients with blood disorders show promise thus far. The joint project between the two firms is taking place at one location in Europe and another in the United States. The results have been posted on the […]
  • Whole-genome sequencing analysis to find more exact biomarkers November 20, 2019
    A new study from Uppsala University shows that whole-genome sequencing increases the precision of genetic studies, which in turn can improve our understanding of how to use biomarkers to discover disease. The results are published in the scientific journal Scientific Reports.
  • Complex organ models grown in the lab November 19, 2019
    Scientists at the University of Würzburg have successfully produced human tissues from stem cells. They have a complexity similar to that of normal tissue and are far superior to previous structures.
  • Outback telescope captures Milky Way center, discovers remnants of dead stars November 20, 2019
    A radio telescope in the Western Australian outback has captured a spectacular new view of the centre of the galaxy in which we live, the Milky Way.The image from the Murchison Widefield Array (MWA) telescope shows what our galaxy would look like if human eyes could see radio waves.
  • Leadership's in the blood for tiny fish November 20, 2019
    Leadership during cooperation runs in the family for tiny fish called Trinidadian guppies, new research shows.
  • Non-invasive microscopy detects activation state and distinguishes between cell types November 20, 2019
    Most analytical methods in biology require invasive procedures to analyze samples, which leads to irreversible changes or even their destruction. Here, researchers from Osaka University develop a non-invasive, label-free optical approach along with statistical tools to reveal immune cell type, cell activation state, and single cell heterogeneity.
  • Living in ethnic enclaves may improve pregnancy outcomes for Asian/Pacific islanders November 20, 2019
    Among Asian/Pacific Islander women living in the United States, those who reside in ethnic enclaves--areas with a high concentration of residents of a similar ancestry--are less likely to have pregnancy or birth complications than those living in other areas, suggests a study by researchers at the National Institutes of Health and other institutions.
  • Study: Young children can learn math skills from intelligent virtual characters November 20, 2019
    A new study examined whether young children's verbal engagement with an onscreen interactive media character could boost their math skills. The study concluded that children's parasocial (that is, one-sided) emotional relationships with the intelligent character and their parasocial interactions (in this case, talking about math with the character) led to quicker, more accurate math responses […]